How I Think
Most people treat industries as context. I treat them as systems; with inputs, constraints, and failure points worth understanding before you try to operate inside them. This page is where I work that out.
Featured Insight
On Compounding & Execution in Healthcare
In healthcare and life sciences, outcomes are built, not discovered. Progress comes from accumulation: small improvements across development, regulatory execution, and commercialization that compound into meaningful impact.
In areas like precision diagnostics and radiopharmaceuticals, execution is what creates separation. Coordination across development, manufacturing, and delivery determines whether innovation actually reaches patients.
Small inefficiencies don’t stay small... they compound... delaying timelines, increasing cost, and limiting scale.
Execution is what determines who delivers, and who doesn’t.
What I'm tracking
Capital allocation and markets: How businesses deploy time, money, and resources determines outcomes more than any single decision. Following how allocation decisions compound across sectors, and how small differences in where capital flows create meaningful separation in performance over time.
Metabolic disease and cell therapy: Following how radiopharmaceutical targeting logic, originally developed for oncology, is being applied to metabolic disease, particularly GLP-1 receptor imaging as a diagnostic tool for beta cell mass in diabetes. Also tracking early-stage clinical development in stem cell-based beta cell replacement for Type 1 diabetes, where the science is advancing faster than the commercial and manufacturing infrastructure around it.
Diagnostics commercialization: How validated tools fail to reach patients at scale, and what the companies that solve it do differently. Reimbursement structure, physician adoption curves, and infrastructure buildout are where most diagnostics stall. The science getting approved is the easier part.
SEC v. Cochran: Tracking the structural implications of this case for regulatory enforcement power and market confidence. Focused on how the outcome shapes the boundaries between agency authority and judicial oversight.
Selected Insights
A few short observations based on what I’m working on and learning.
On Markets & Consumer Behavior
Markets don’t move in isolation, they reflect changes in consumer behavior. When spending slows, it shows up quickly in revenue, margins, and valuations. Small shifts in confidence can ripple across sectors before the data fully catches up. Understanding those signals is as important as understanding the companies themselves.
On Rejection & Performance
In performance-driven environments, avoiding rejection often means avoiding opportunity. Increasing volume; more conversations, more attempts, improves both outcomes and skill through repetition. The constraint isn’t failure, it’s hesitation.
On Healthcare & Execution
In healthcare and life sciences, outcomes depend on more than innovation. The companies that scale are the ones that can execute; navigating complexity, aligning decisions, and consistently delivering in high-stakes environments.
On Compounding Decisions
Small advantages, repeated consistently, compound into meaningful results over time. Across sales, investing, and operations, sustained execution creates more separation than any single decision.
On Capital Allocation
At a high level, every business decision is a capital allocation decision, where time, money, and resources are deployed. The companies that outperform aren’t just generating returns, they’re consistently allocating capital to the highest-value opportunities. Small differences in allocation decisions compound over time, creating meaningful separation in performance.